All In Biotech

Drug Trial Radar · NCT00475085

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

Last checked: Nov 19, 2026Latest source record: Nov 10, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,021 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,021

Actual

Start

Dec 2006

Primary completion

Dec 2012

Sponsor

Lead sponsor
Joseph RoscoeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
May 17, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Supportive care
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Antiemetic drugs, such as granisetron, dexamethasone, prochlorperazine, aprepitant, and palonosetron, may help lessen or prevent nausea. It is not yet known which combination of antiemetic drugs is more effective in preventing nausea caused by chemotherapy. PURPOSE: This randomized phase III trial is comparing different combinations of granisetron, dexamethasone, prochlorperazine, aprepitant, and palonosetron to see how well they work in preventing nausea in patients undergoing chemotherapy for breast cancer.

Conditions

  • Nausea

Interventions

  • aprepitantDrug

    Given orally or IV

  • dexamethasoneDrug

    Given orally or IV

  • granisetron hydrochlorideDrug

    Given orally or IV

  • palonosetron hydrochlorideDrug

    Given orally or IV

  • prochlorperazineDrug

    Given orally or IV

  • placeboDrug

    Given orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Home Record: Severity of Delayed NauseaTime frame: average of day 1 afternoon, evening and night, and all of days 2 and 3

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • MBCCOP - Gulf Coast

    Mobile, Alabama

  • CCOP - Central Illinois

    Decatur, Illinois

  • CCOP - Wichita

    Wichita, Kansas

  • CCOP - Grand Rapids

    Grand Rapids, Michigan

  • CCOP - Kalamazoo

    Kalamazoo, Michigan

  • CCOP - Metro-Minnesota

    Saint Louis Park, Minnesota

  • CCOP - Kansas City

    Kansas City, Missouri

  • CCOP - Nevada Cancer Research Foundation

    Las Vegas, Nevada

  • CCOP - Hematology-Oncology Associates of Central New York

    East Syracuse, New York

  • CCOP - North Shore University Hospital

    Manhassett, New York

  • CCOP - Southeast Cancer Control Consortium

    Goldsboro, North Carolina

  • CCOP - Columbus

    Columbus, Ohio

  • CCOP - Dayton

    Dayton, Ohio

  • CCOP - Greenville

    Greenville, South Carolina

  • CCOP - Northwest

    Tacoma, Washington

  • CCOP - Marshfield Clinic Research Foundation

    Marshfield, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.